| Literature DB >> 25152902 |
Naguib Salleh1, Nelli Giribabu1.
Abstract
Leukaemia inhibitory factor (LIF) plays an indispensible role in embryo implantation. Aberrant LIF production is linked to implantation failure. LIF regulates multiple processes prior to and during implantation such as uterine transformation into a receptive state, decidualization, blastocyst growth and development, embryo-endometrial interaction, trophoblast invasion, and immune modulation. Due to its critical role, LIF has been a target for a nonhormonal contraception. In this review, we summarize up-to-date information on the role of LIF in implantation and its role in contraception.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25152902 PMCID: PMC4131495 DOI: 10.1155/2014/201514
Source DB: PubMed Journal: ScientificWorldJournal ISSN: 1537-744X
Figure 1Summary of the known roles of LIF in embryo implantation. LIF increases the expression of EGF and implantation genes in receptive endometrium. LIF produced by endometrium and blastocyst regulates growth and development of the embryo. Meanwhile, LIF stimulates stromal decidualization by increasing the production of cytokines and prostaglandins. LIF is also involved in enhancing embryo-endometrial interaction through pinopodes and adhesion molecules. LIF stimulates trophoblast cells differentiation and increase trophoblast capability to invade the uterine stroma. Finally, LIF is involved in recruitment of specific cohort of leucocytes which participates in inflammatory response during implantation. LIF: leukemia inhibitory factor, HB-EGF: heparin binding-epidermal growth factor, Ereg: epiregulin, Ar: amphiregulin, E2: estrogen, P4: progesterone, IL: interleukins, PGs: prostaglandins, COX: cyclo-oxygenase, NK: natural killer, PPAR: peroxisome proliferator-activated receptor, PGE2: prostaglandins E2, hCG: human chorionic gonadotrophin, MUC: mucin, JAM: junctional adhesion molecules.
Summary of the literatures that reported the use of LIF antagonist in preventing implantation in different models. So far, only one study has been performed on human uterine tissues in-vitro which investigated this effect.
| Authors | Antagonist | Route of administration | Detectable in uterine tissue | Model | Effects |
|---|---|---|---|---|---|
|
Aschenbach et al. (2013) [ | PEGLA | Intramuscular and subcutaneous | Yes | Cynomolgus monkeys | Reduced endometrial STAT3 protein phosphorylation |
| Vaginal | No | ||||
|
| |||||
| Menkhorst et al. (2011) [ | PEGLA | Vaginal | Yes | Mice | Blocked implantation |
|
| |||||
|
White et al. (2007) [ | LIF antagonist (LA) | Intraperitoneal plus continuous administration via miniosmotic pump | Mice | Blocked implantation | |
| PEGLA | Intraperitoneal | Yes; uterine luminal epithelium (no systemic side effects) | Mice | Inhibited implantation | |
|
| |||||
| Lalitkumar et al. (2013) [ | PEGLA |
| Yes | Human | Reduced embryo attachment rate to endometrium |
|
| |||||
| Sengupta et al. (2006) [ | Anti-LIF monoclonal Ab | Intrauterine | Yes | Rhesus Monkey | Significant decline in pregnancy outcome |